IP50-24: Clinical Outcomes of Nadofaragene Firadenovac in BCG Unresponsive NMIBC: A Multi-Center analysis

IP50-24: Clinical Outcomes of Nadofaragene Firadenovac in BCG Unresponsive NMIBC: A Multi-Center analysis

Sunday, May 17, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)

146A

Abstract

Speakers

Abhilash Moolupuri

Abhilash Moolupuri

ResidentUniversity of Tennessee, Knoxville

Sessions

IP50: Bladder Cancer: Non-invasive IV

Sunday, May 17, 2026 7:00 AM to 9:00 AM

Christopher Anderson · Columbia University Medical Center

William Tabayoyong · Department of Urology

Mary Westerman · Department of Urology, University of North Carolina

Registered attendees

Scott Flanders

VP of Medical AffairsImmunityBio, Inc.

Log in

See all the content and easy-to-use features by logging in or registering!